[HTML][HTML] Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II …
V González-Calle, P Rodríguez-Otero, A Sureda… - …, 2024 - ncbi.nlm.nih.gov
The treatment landscape for multiple myeloma has significantly evolved in the last decade.
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non …
V González-Calle, P Rodríguez-Otero, A Sureda… - …, 2024 - europepmc.org
The treatment landscape for multiple myeloma has significantly evolved in the last decade.
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non …
V González-Calle, P Rodríguez-Otero, A Sureda… - …, 2020 - haematologica.org
The treatment landscape for multiple myeloma has significantly evolved in the last decade.
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non …
V González-Calle, P Rodríguez-Otero, A Sureda… - … - pubmed.ncbi.nlm.nih.gov
The treatment landscape for multiple myeloma has significantly evolved in the last decade.
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …
Notwithstanding, a large proportion of patients continue to relapse and novel combinations …